Invivyd has appointed Dr. Akiko Iwasaki, a renowned immunobiologist from Yale School of Medicine, to its SPEAR Study Group. The group focuses on the biological and clinical implications of persistent spike protein presence post SARS-CoV-2 infection or vaccination, conditions linked to Long COVID and COVID-19 Post-Vaccination Syndrome (PVS). Dr. Iwasaki’s expertise in viral pathogenesis, immunobiology, and post-viral conditions, including her leadership in Long COVID research at Yale, makes her a valuable addition to the team.
This appointment underscores the growing recognition of Long COVID and PVS as significant public health concerns with complex biological underpinnings. Dr. Iwasaki’s participation lends considerable scientific weight to Invivyd’s efforts and signals a serious commitment to understanding and potentially treating these conditions. This move could accelerate research and development in this critical area, potentially leading to much-needed therapies for millions experiencing lingering symptoms.
The SPEAR Study Group is investigating the potential of monoclonal antibodies, specifically Invivyd’s investigational VYD2311, to address Long COVID and PVS. This research is driven by anecdotal reports and emerging mechanistic research suggesting persistent spike protein as a possible therapeutic target. VYD2311 is being explored due to its potential for improved administration compared to other antibodies, building on the experience with Invivyd’s previously authorized antibody, PEMGARDA, though it’s crucial to note that PEMGARDA is not currently authorized for this purpose.
Dr. Iwasaki’s addition to the SPEAR Study Group positions Invivyd as a key player in the Long COVID and PVS therapeutic landscape. Her expertise, combined with Invivyd’s monoclonal antibody platform, may accelerate the development of effective treatments, offering hope to patients and potentially transforming how these post-viral conditions are managed. This research could also significantly impact our understanding of Long COVID and PVS, shaping future research and clinical practice.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
